IDH1/2 mutations in patients with diffuse gliomas: A single centre retrospective massively parallel sequencing analysis
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F22%3A73610228" target="_blank" >RIV/61989592:15110/22:73610228 - isvavai.cz</a>
Alternative codes found
RIV/70883521:28150/21:63535058 RIV/00098892:_____/22:10157737
Result on the web
<a href="https://journals.lww.com/appliedimmunohist/Fulltext/2022/03000/IDH1_2_Mutations_in_Patients_With_Diffuse_Gliomas_.4.aspx" target="_blank" >https://journals.lww.com/appliedimmunohist/Fulltext/2022/03000/IDH1_2_Mutations_in_Patients_With_Diffuse_Gliomas_.4.aspx</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1097/PAI.0000000000000997" target="_blank" >10.1097/PAI.0000000000000997</a>
Alternative languages
Result language
angličtina
Original language name
IDH1/2 mutations in patients with diffuse gliomas: A single centre retrospective massively parallel sequencing analysis
Original language description
Patients below 55 years were genetically studied because the prevalence of isocitrate dehydrogenase 1 (IDH1) decreases in older patients and on grounds of cost-effectiveness, as suggested by the World Health Organization (WHO) in 2016. The aim of our study was to use novel massively parallel sequencing (MPS) approaches to examine rare variants of IDH1/2 in Czech diffuse astrocytic and oligodendroglial tumors (gliomas) patients below 55 years of age who had been immunohistochemically (IHC) diagnosed as IDH1 R132H negative. The IHC IDH1 status (wild type or mutant) of 275 tissue samples was analyzed using antibodies against the IDH1 R132H protein. Sixty-three samples of 55 years old patients with IHC IDH1 WT status were genotyped using two different MPS technologies to detect rare IDH1 and IDH2 variants. The tiered IHC (60 positive) and molecular (10 positive) approach thus revealed that 70 of the 275 samples (25%) bore IDH1/IDH2 mutations. The combined molecular and IHC approach thus revealed that 70 of the 275 samples (25%) considered in the study bore IDH1/IDH2 mutations. IHC detection of the IDH1 R132H variant should be routinely complemented with MPS to detect rare IDH1/2 variants in glioma patients below 55 years of age with negative IHC result of IDH R132H variant.
Czech name
—
Czech description
—
Classification
Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30109 - Pathology
Result continuities
Project
Result was created during the realization of more than one project. More information in the Projects tab.
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)
Others
Publication year
2022
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY
ISSN
1541-2016
e-ISSN
1533-4058
Volume of the periodical
30
Issue of the periodical within the volume
3
Country of publishing house
US - UNITED STATES
Number of pages
6
Pages from-to
178-183
UT code for WoS article
000766274300005
EID of the result in the Scopus database
2-s2.0-85121040979